
Dina Radenkovic, Gameto CEO
Bob Nelsen, Anne Wojcicki join $20M round for longevity startup hoping to slow down aging of the ovary
Having helped birth some of the earliest anti-aging upstarts, Bob Nelsen has found another new idea to love in the burgeoning space.
The ARCH managing director is among a syndicate pouring $20 million of Series A cash into Gameto, a New York-based biotech whose stated mission is to reprogram ovarian cells to slow down the aging of the ovary — which is very much “accelerated” compared to other organs, according to the company.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters